NEW YORK (TheStreet) -- Medtronic (MDT) - Get Report shares closed trading up 1.38% to $77.53 on Monday after the medical device maker released two years of data from tests conducted on its transcatheter aortic valve replacement (TAVR) that showed it was a better alternative to surgical aortic valve replacement surgery.

The findings of the study showed that the TAVR's in patients who were too high risk to be surgical candidates showed durability two years after the device was installed.

The company reported that the all-cause mortality or stroke rate of patients treated with the device as opposed to surgery was 24.2% while the rate for patients treated surgically was 32.5%.

"This data is strong enough that it should change our guidelines in the increased risk surgical population where TAVR is not just an alternative to surgery, but it should be the preferred option," said Dr. Michael Reardon, the lead investigator of the study.

TheStreet's Jim Cramer, Portfolio Manager of the Action Alerts Plus charitable trust, believes that the company's value has only been enhanced since last year's tax inversion deal.

"The changed tax status has only enhanced the value of Medtronic, as it now pays much less via the tax inversion that Medtronic availed itself of before the change in the laws," said Cramer.

TheStreet Ratings team rates MEDTRONIC PLC as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:

"We rate MEDTRONIC PLC (MDT) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• MDT's revenue growth has slightly outpaced the industry average of 1.1%. Since the same quarter one year prior, revenues slightly increased by 3.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
• Powered by its strong earnings growth of 30.66% and other important driving factors, this stock has surged by 28.29% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, MDT should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
• The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry average. The net income increased by 28.2% when compared to the same quarter one year prior, rising from $762.00 million to $977.00 million.
• Net operating cash flow has slightly increased to $1,767.00 million or 9.61% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -7.31%.
• You can view the full analysis from the report here: MDT Ratings Report